Volociximab

Volociximab
Monoclonal antibody
Type	Whole antibody
Source	Chimeric (mouse/human)
Target	α5β1 integrin
Clinical data
ATC code	none;
Identifiers
CAS Number	558480-40-3 ;
ChemSpider	none;
UNII	496K5Z02NW;
KEGG	D06319 ;
Chemical and physical data
Formula	C6434H9942N1706O2040S52
Molar mass	145.5 kg/mol g·mol−1
(what is this?) (verify)

Volociximab (also known as M200) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin.[1]

It is thought to reduce metastases. Early results show potential in renal cell cancers.

References

Ng, CM; Bai, S; Takimoto, CH; Tang, MT; Tolcher, AW (2009). "Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-alpha(5)beta (1) integrin monoclonal antibody (volociximab) in cancer patients". Cancer Chemotherapy and Pharmacology. 65 (2): 207–17. doi:10.1007/s00280-009-1023-8. PMID 19468731.

External links

Official website

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Ng, CM; Bai, S; Takimoto, CH; Tang, MT; Tolcher, AW (2009). "Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-alpha(5)beta (1) integrin monoclonal antibody (volociximab) in cancer patients". Cancer Chemotherapy and Pharmacology. 65 (2): 207–17. doi:10.1007/s00280-009-1023-8. PMID 19468731.